Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05601063
Other study ID # 20-0468
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 1, 2020
Est. completion date September 1, 2022

Study information

Verified date October 2022
Source Northwell Health
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Cross-sectional observational study of the relationship between speech patterns and psychiatric symptoms and disorders.


Description:

Major psychiatric disorders often occur together in the same patient and it can be difficult to distinguish between disorders with overlapping symptoms. The majority of patients with mental illness receive treatment in settings where it is not feasible to conduct detailed diagnostic interviews or neuropsychiatric testing. A cost-effective and efficient tool is needed for accurate diagnosis. Looking at language is an efficient way of making sense of the brain because it is easily observed and reflects brain circuitry. Automated natural language processing (NLP) can help us do this objectively, efficiently, and with high sensitivity. The investigators aim to use linguistic features extracted using natural language processing to aid in diagnostic classification and in predicting dimensional symptoms. This will be done by obtaining clinical diagnoses, language samples, and self-report scales from 604 participants with a variety of psychiatric symptoms. Adolescents will also be included and the investigators will try to predict diagnosis in adolescents using models that were built on adult data.


Recruitment information / eligibility

Status Completed
Enrollment 255
Est. completion date September 1, 2022
Est. primary completion date September 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 14 Years to 50 Years
Eligibility Inclusion Criteria: - Speaks with conversational proficiency with conversational proficiency - Current diagnosis in the medical chart of any of the following. The patient may be in partial but not full remission. Comorbidity among these disorders and other unlisted disorders is expected and allowable. - Schizophrenia-spectrum disorder - schizophrenia, schizophreniform, schizoaffective disorder, delusional disorder, brief psychotic disorder, or unspecified psychotic disorder - Bipolar spectrum disorder - bipolar I or II disorder, cyclothymia, unspecified or other specified bipolar disorder - (Unipolar) Depressive disorder - major depressive disorder, dysthymia, unspecified and other specified depressive disorder - Anxiety disorder - obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, post-traumatic stress disorder - Personality disorder - borderline personality disorder - Attention-Deficit Hyperactivity Disorder - Healthy comparison subjects - Age 14 - 50 years - Has capacity and willing to sign informed consent; if minor, parent is willing to give consent and child is willing to give assent. - Screening will not include a pregnancy test. Pregnant women will not be screened out of the study because the study procedures are of very low risk overall, and pregnancy does not place the participant or the fetus at any significant risk. - Minors will be included in the study because diagnostic ambiguity is prevalent before the age of 18 and this patient group is particularly in need of accurate prognosis and treatment. Therefore, it is of vital importance that the conclusions of the study be applicable to minors and that they be included among the participants. Exclusion Criteria: - Participants with substance-induced disorders or disorders secondary to a general medical condition will not be included as underlying brain changes may be different from "primary" psychiatric disorders. - Disorders affecting speech or language, such as aphasia, intellectual disability (IQ<70), or language disorder, or movement disorders affecting speech like tardive dyskinesia, or physical impairments causing significant distortions to speech - Serious neurological or endocrine disorder or any medical condition or treatment known to affect the brain and/or language, including but not limited to: neurodegenerative disorders, traumatic brain injury with active symptoms, autism spectrum disorder, encephalitis, epilepsy - Cognitive or language limitations, or any other factor that would preclude subjects providing informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Winterlight Speech Assessment
Digital assessment of speech and language abilities

Locations

Country Name City State
United States Zucker Hillside Hospital Glen Oaks New York

Sponsors (2)

Lead Sponsor Collaborator
Northwell Health Winterlight Labs

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Speech features from the Winterlight Speech Assessment Acoustic and linguistic measures of speech computed based on performance on the Winterlight Speech Assessment Baseline
Secondary Brief Symptom Inventory 53 item. Range = 0, not at all - 4, extremely. Higher scores resulting in worse outcome.
TLC: Scale for the Assessment of Thought Language and Communication
Baseline
Secondary Patient Health Questionnaire - 9 9 item. Range = 0, not at all - 3, nearly every day. Higher scores resulting in worse outcome. Baseline
Secondary Generalized Anxiety Disorder - 7 7 item. Range = 0, not at all - 3, nearly every day. Higher scores resulting in worse outcome. Baseline
Secondary Prodromal Questionnaire - Brief 18 item. Range = 0, no - 1, yes. Higher scores resulting in worse outcome. Baseline
Secondary Scale for the Assessment of Thought Language and Communication 20 item, range= 0, absent - 3, severe; higher scores resulting in worse outcome. Baseline
See also
  Status Clinical Trial Phase
Recruiting NCT06129396 - Effects of Aerobic Exercise Intervention in Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD) N/A
Completed NCT04779333 - Lifestyle Enhancement for ADHD Program 2 N/A
Recruiting NCT05935722 - Evaluation of a Home-based Parenting Support Program: Parenting Young Children N/A
Completed NCT03148782 - Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase N/A
Completed NCT04832737 - Strength-based Treatment Approach for Adults With ADHD N/A
Recruiting NCT04631042 - Developing Brain, Impulsivity and Compulsivity
Recruiting NCT05048043 - Development of a Game-supported Intervention N/A
Completed NCT03337646 - Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism Phase 4
Not yet recruiting NCT06080373 - Formulation-based CBT for Adult Inmates With ADHD: A Randomized Controlled Trial N/A
Completed NCT02911194 - a2 Milk for Autism and Attention-deficit Hyperactivity Disorder (ADHD) N/A
Completed NCT02477280 - Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance Phase 4
Completed NCT02829970 - Helping College Students With ADHD Lead Healthier Lifestyles N/A
Completed NCT02555150 - A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD Phase 3
Completed NCT02473185 - Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the QbTest Phase 4
Completed NCT02390791 - New Technologies to Help Manage ADHD N/A
Completed NCT02780102 - Cognitive-Motor Rehabilitation, Stimulant Drugs, and Active Control in the Treatment of ADHD N/A
Recruiting NCT04175028 - Neuromodulation of Executive Function in the ADHD Brain N/A
Recruiting NCT04296604 - Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations N/A
Completed NCT05138224 - Prevalence of Autistic Spectrum Disorder (ASD) in Children With Haemophilia
Terminated NCT02259517 - An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD N/A